Rheumatological manifestations in inflammatory bowel disease

Annals of Gastroenterology

Volumn 24, Issue 3, 2011, Pages 173-180

  Voulgari, Paraskevi V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Axial involvement; Enthesitis; Peripheral arthritis; Sacroiliitis

Indexed keywords

ACUTE PHASE PROTEIN; ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; CELECOXIB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; HLA B44 ANTIGEN; HLA DR ANTIGEN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; VALDECOXIB;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; ARTICLE; CARDIOTOXICITY; CLINICAL FEATURE; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ENTHESOPATHY; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL SYMPTOM; GENETIC MARKER; HUMAN; HYPERTROPHIC OSTEOARTHROPATHY; MUSCULOSKELETAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PELVIS RADIOGRAPHY; PHYSIOTHERAPY; PREVALENCE; RISK FACTOR; SACROILIITIS; SEX RATIO; SPINE RADIOGRAPHY; SPONDYLITIS; SPONDYLOARTHROPATHY; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 79961241624     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004;10:207-214
2. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401-412
3. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005;129:827-836
4. Bargen JA. Complications and sequelae of chronic ulrcerative colitis. Ann Intern Med 1929;3:335
5. Hench PS. Acute and chronic arthritis. In: Whipple GH (ed). Nelson's looseleaf of surgery I. Thomas Nelson Sons: New York 1935;104
6. Wright V. Seronegative polyarthritis: a unified concept. Arthritis Rheum 1978;21:619-633
7. Acheson Ed. An association between ulcerative colitis, regional enteritis, and ankylosing spondylitis. Q J Med 1960;29:489-499
8. Ansell BM, Wigley RA. Arthritic manifestation in regional enteritis. Ann Rheum Dis 1964;23:64-72
9. Haslock I. Arthritis and Crohn's disease. A family study. Ann Rheum Dis 1973;32:479-486.
10. Wright V, Watkinson G. Sacro-iliitis and ulcerative colitis. Br Med J 1965;2:675-680
11. Wright V, Watkinson G. The arthritis of ulcerative colitis. Br Med J 1965;2:670-675
12. Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-920
13. Münch H, Purrmann J, Reis HE, et al. Clinical features of inflammatory joint and spine manifestations in Crohn's disease. Hepatogastroenterology 1986;33:123-127
14. Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Agenant D, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis 1978;37:33-35
15. Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009;15:2449-2455
16. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-1227
17. Amor B. [Very early diagnosis of chondrolysis phases in arthrosis]. Rev Rhum Mal Osteoartic 1990;57:253-254
18. Scarpa R, del Puente A, D'Arienzo A, et al. The arthritis of ulcerative colitis: clinical and genetic aspects. J Rheumatol 1992;19:373-377
19. Protzer U, Duchmann R, Höhler T, et al. [Enteropathic spondylarthritis in chronic inflammatory bowel diseases: prevalence, manifestation pattern and HLA association]. Med Klin (Munich) 1996;91:330-335
20. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996;23:29-34
21. Suh CH, Lee CH, Lee J, et al. Arthritic manifestations of inflammatory bowel disease. J Korean Med Sci 1998;13:39-43
22. de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000;27:2860-2865
23. Queiro R, Maiz O, Intxausti J, et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clin Rheumatol 2000;19:445-449
24. Christodoulou DK, Katsanos KH, Kitsanou M, Stergiopoulou C, Hatzis J, Tsianos EV. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig Liver Dis 2002;34:781-786
25. Palm Ø, Moum B, Jahnsen J, Gran JT. The prevalence and incidence of peripheral arthritis in patients with inflammatory disease a prospective population-based study (the IBSEN study) Rheumatology (Oxford) 2001;40:1256-1261
26. Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Díaz-Rubio M. [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis]. Med Clin (Barc) 2005;125:297-300
27. Peeters H, Vander Cruyssen B, Mielants H, et al. Clinical and genetic factors associated with sacroiliitis in Crohn's disease. J Gastroenterol Hepatol 2008;23:132-137
28. Rodriguez VE, Costas PJ, Vazquez M, et al. Prevalence of spondyloarthropathy in Puerto Rican patients with inflammatory bowel disease. Ethn Dis 2008;18(2 suppl 2):225-229
29. Lanna CC, Ferrari Mde L, Rocha SL, Nascimento E, de Carvalho MA, da Cunha AS. A cross-sectional study of 130 Brazilian patients with Crohn's disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol 2008;27:503-509
30. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998;42:387-391
31. Salvarani C, Vlachonikolis IG, van der Heijde DM, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001;36:1307-1313
32. Türkçapar N, Ozyüncü N, Idilman R, Ensari A, Soylu K, Ozden A. Macro-amylasemia in a patient with selective IgA deficiency and antiphospholipid antibodies. Turk J Gastroenterol 2006;17:140-143
33. Mielants H, Veys EM, Cuvelier C, De Vos M, Botelberghe L. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol 1985;12:294-298
34. Veloso FT, Fraga J, Saleiro JV.Macroglobulinemia and small intestinal disease. A case report with review of the literature. J Clin Gastroenterol 1988;10:546-550
35. Mielants H, Veys EM. The gut in the spondyloarthropathies. J Rheumatol 1990;17:7-10
36. Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003;30:518-522
37. Podswiadek M, Punzi L, Stramare R, et al. The prevalence of radiographic sacroiliitis in patients affected by inflammatory bowel disease with inflammatory low back pain. Reumatismo 2004;56:110-113
38. Mielants H. Reflections on the link between intestinal permeability and inflammatory joint disease. Clin Exp Rheumatol 1990;8:523-524
39. Scott WW Jr, Fishman EK, Kuhlman JE, et al.Computed tomography evaluation of the sacroiliac joints in Crohn disease. Radiologic/clinical correlation.Skeletal Radiol 1990;19:207-210
40. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006;101:1012-1023
41. Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005;100:2254-2261.
42. Mahid SS, Mulhall AM, Gholson RD, Eichenberger MR, Galandiuk S. Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis 2008;14:960-967
43. Repiso A, Alcántara M, Muñoz-Rosas C, et al. Extraintestinal manifestations of Crohn's disease: prevalence and related factors. Rev Esp Enferm Dig 2006;98:510-517
44. Dorofeyev AE, Vasilenko IV, Rassokhina OA. Joint extraintestinal manifestations in ulcerative colitis. Dig Dis 2009;27:502-510
45. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:36-42
46. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12:4819-4831
47. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11: 7227-7236
48. Maeda K, Okada M, Yao T, et al. Intestinal and extraintestinal complications of Crohn's disease: predictors and cumulative probability of complications. J Gastroenterol 1994; 29: 577-582
49. Triantafillidis JK, Emmanouilidis A, Manousos O, Nicolakis D, Kogevinas M. Clinical patterns of Crohn's disease in Greece: a follow-up study of 155 cases. Digestion 2000;61:121-128
50. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-1122
51. Souza MH, Troncon LE, Rodrigues CM, et al. Trends in the occurrence (1980-1999) and clinical features of Crohn's disease and ulcerative colitis in a university hospital in southeastern Brazil. Arq Gastroenterol 2002;39:98-105
52. Al-Shamali MA, Kalaoui M, Patty I, Hasan F, Khajah A, Al-Nakib B. Ulcerative colitis in Kuwait: a review of 90 cases. Digestion 2003;67:218-224
53. Economou M, Filis G, Tsianou Z, et al. Crohn's disease incidence evolution in North-western Greece is not associated with alteration of NOD2/CARD15 variants. World J Gastroenterol 2007;13:5116-5120
54. Peeters H, Vander Cruyssen B, Laukens D, et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis 2004;63:1131-1134
55. Peeters H, Vander Cruyssen B, Mielants H, et al. Clinical and genetic factors associated with sacroiliitis in Crohn's disease. J Gastroenterol Hepatol 2008;23:132-137
56. Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:597-605
57. Travis SP, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55(Suppl 1):i16-i35
58. Wordsworth P. Arthritis and inflammatory bowel disease. Curr Rheumatol Rep 2000;2:87-88
59. Fomberstein B, Yerra N, Pitchumoni CS. Rheumatological complications of GI disorders. Am J Gastroenterol 1996;91:1090-1103
60. Klippel JH Dieppe RA. Rheumatology (2nd edition). Mosby: London 1998; 6.24.1-6.24.3
61. Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 2001;44:2728-2736
62. Moll JM. Inflammatory bowel disease. Clin Rheum Dis 1985;11:87-111
63. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppälä K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994;37:23-31
64. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569-578
65. Bennett PH. Wood PHN population studies of the rheumatic diseases Amsterdam. Excerpta Medical Fountation 1968;456-457
66. Braun J, Sieper J. Early diagnosis of spondyloarthritis. Nat Clin Pract Rheumatol 2006;2:536-545
67. Klippel JH, Stone JH, Crofford LJ, White PH. Primer on the rheumatic diseases (13th. Springer: New York 2008;204-205
68. Hamersma J, Cardon LR, Bradbury L, et al. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum 2001;44:1396-1400
69. Brown MA. Non-major-histocompatibility-complex genetics of ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006;20:611-621
70. Brown MA, Brophy S, Bradbury L, et al. Identification of major loci controlling clinical manifestations of ankylosing spondylitis. Arthritis Rheum 2003;48:2234-2239
71. Fornaciari G, Salvarani C, Beltrami M, Macchioni P, Stockbrügger RW, Russel MG. Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001;15:399-403
72. Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000;118:274-278
73. Cuvelier CA, Quatacker J, Mielants H, De Vos M, Veys E, Roels HJ. M-cells are damaged and increased in number in inflamed human ileal mucosa. Histopathology 1994;24:417-426
74. Salmi M, Andrew DP, Butcher EC, Jalkanen S. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med 1995;181:137-149
75. Van den Broek MF, Van de Putte LB, Van den Berg WB. Crohn's disease associated with arthritis: a possible role for cross-reactivity between gut bacteria and cartilage in the pathogenesis of arthritis. Arthritis Rheum 1988;31:1077-1079
76. Elewaut D, De Keyser F, Van Den Bosch F, et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998;25:1932-1937
77. Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol 2001;166:4650-4657
78. May E, Märker-Hermann E, Wittig BM, Zeitz M, Meyer zum Büschenfelde KH, Duchmann R. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 2000;119:1745-1755
79. Kaufman HL, Fischer AH, Carroll M, Becker JM. Colonic ulceration associated with nonsteroidal anti-inflammatory drugs. Report of three cases. Dis Colon Rectum 1996;39:705-710
80. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-516
81. O'Brien J. Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000;95:1859-1861
82. Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 2001;44:2728-2736
83. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo controlled, pilot study. Clin Gastroenterol Hepatol 2006;4:203-211
84. Biancone L, Tosti C, Geremia A, et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther 2004;19:755-764
85. De Keyser F, Van Damme N, De Vos M, Mielants H, Veys EM. Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm Res 2000;49:47-54
86. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000;356:1821-1822
87. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004;63:1664-1669
88. Rispo A, Scarpa R, Di Girolamo E, et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 2005;34:387-391
89. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003;62:74-76
90. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010;32:384-393
91. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8:688-695
92. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31:92-101